Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Park

Vascular Surgery Sacramento, CA Medical Doctor

NPI 1508918616 CMS profile 1089492

2725 Capitol Ave Dept 402, Sacramento, CA 95816

Open in the dashboard

General payments

$5,404

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Park of Sacramento, CA is reported in the CMS Open Payments database as having received $5,404 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 3
2024 General $1,846 11
2023 General $998 14
2022 General $572 6
2021 General $88 5
2020 General $23 1
2019 General $1,755 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Park
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Brian Park were reported at $122. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Brian Park Vascular Surgery median Middle half National median
2019 $1,755 $796 $226–$2,363 $163
2020 $23 $348 $118–$1,110 $114
2021 $88 $471 $158–$1,421 $132
2022 $572 $725 $222–$2,183 $149
2023 $998 $836 $257–$2,440 $160
2024 $1,846 $909 $252–$2,619 $164
2025 $122 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,513 31 payments
  2. Silk Road Medical, Inc. $602 4 payments
  3. Boston Scientific Corporation $503 12 payments
  4. Medtronic, Inc. $308 2 payments
  5. Medtronic Vascular, Inc. $147 3 payments
  6. Terumo Medical Corporation $109 1 payment
  7. LeMaitre Vascular, Inc. $98 5 payments
  8. Organogenesis Inc. $46 1 payment
  9. Janssen Pharmaceuticals, Inc $46 1 payment
  10. Johnson & Johnson Vision Care, Inc. $18 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,156 57 payments
  2. Travel and Lodging $1,202 4 payments
  3. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. GORE TAG Thoracic Branch Endoprosthesis $1,140 6 payments
  2. EXCLUDER Iliac Branch Endoprosthesis $890 11 payments
  3. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $639 5 payments
  4. ELUVIA $479 11 payments
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $430 3 payments
  6. ENROUTE Transcarotid Stent $430 3 payments
  7. EXCLUDER Conformable AAA Endoprosthesis with Active Control $426 4 payments
  8. EXCLUDER AAA Endoprosthesis $266 2 payments
  9. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $206 1 payment
  10. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $206 1 payment
  11. Other $1,651 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

405

Median for Vascular Surgery: 122

Drug cost

$84,925

Median for Vascular Surgery: $14,135

Branded share of claims

61.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 79 $56,491
Xarelto Rivaroxaban Brand 39 $25,345
Cilostazol Generic 84 $1,627
Clopidogrel Clopidogrel Bisulfate Brand 104 $818
Atorvastatin Calcium Generic 46 $319
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $145
Bisoprolol Fumarate Generic 12 $123
Amlodipine Besylate Generic 13 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$315,672

Medicare's payments for the services billed

Medicare patients

1,028

Average age 77

Services billed

2,342

427 women, 601 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 52%
Chronic kidney disease 43%
Diabetes 40%
Atrial fibrillation 30%
COPD 29%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record